ASA Submits Comments to FDA on Opioid REMS
(July 10, 2009)
ASA recently submitted comments to the Food and Drug Administration (FDA) in response to a Federal Register notice seeking guidance on the Agency’s proposed plan for developing Risk Evaluation and Mitigation Strategies (REMS) for certain long-acting and high-potency opioids. FDA has been holding various stakeholder meetings on this issue for several months to gain public feedback on how best to enact congressionally authorized options for reducing abuse, diversion and unintended deaths associated with opioid medications. ASA is concerned that if FDA enacts burdensome prescribing or certification requirements for only certain opioids, pain specialists will be overwhelmed with patients as primary care and other physicians opt out of prescribing these medications. In addition ASA believes such burdensome requirements will drive up abuse of other less-regulated opioids that are already the most commonly abused.
ASA’s Committee on Pain Medicine contributed considerably in the drafting of the comments.
THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS
Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.
For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org . To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Like ASA on Facebook , follow ASALifeline on Twitter and follow ASA on LinkedIn .